Recent

% | $
Quotes you view appear here for quick access.

Immune Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • larshansson18 larshansson18 Aug 25, 2009 4:23 PM Flag

    Jack "amateur" Talley

    You missed my question. I did not ask anything about Epicepts management, I asked a question that relates to the relation between the demanding patients and IDIS.

    So I repeat:

    "What is your prediction about the sales of Ceplene through IDIS reported next Q-report?"

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The sales are in direct relation to the management.

      So the answer is - whatever you expect - the answer
      is disappointing.

      They already had enough time to force sales via IDIS -
      but no sales were reported last webcast - so its not mentionable.

      More than a year after approval, they did not
      confirm a single sale. Not to mention partnership.

    • Lars - he's a short - he will never answer anything in a definative way regarding revenues. Are you kidding, he just wants to destabilize things on the board. Create fear and uncertainty, scare potential new investors etc.

      But he is about to get his butt kicked cause interest is creeping back in as witnessed by the slowly increasing trade volume the past couple of days.

      .... and its just about to become painful, so quick the charades and cover shorty!!

      Root

    • "So I repeat:

      "What is your prediction about the sales of Ceplene through IDIS reported next Q-report?" "


      Since you know so much about EPCT, why not share your number here?

      BTW: You can save the sale number in case nothing come out for next Q. The good thing is there is always NEXT Q. So, eventually you have great chance to be right. :)

 
IMNP
0.3812-0.0598(-13.56%)Jun 24 4:00 PMEDT